Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. Tiberi S, et al. Among authors: de lorenzo s, de vries g. Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. Clin Infect Dis. 2016. PMID: 26908794 No abstract available.
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. Tiberi S, et al. Among authors: de lorenzo s, de vries g. Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10. Eur Respir J. 2016. PMID: 26965290 Free article.
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. Tiberi S, et al. Among authors: de lorenzo s, de vries g. Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13. Eur Respir J. 2016. PMID: 27076583 Free article.
Consensus not yet reached on key drugs for extensively drug-resistant tuberculosis treatment.
Migliori GB, Sotgiu G, D'Arcy Richardson M, Centis R, Guenther G, Hoffmann H, Cirillo DM, Toungossova O, Kliiman K, De Lorenzo S, Spanevello A, Lange C; Tuberculosis Network European Trialsgroup. Migliori GB, et al. Among authors: de lorenzo s. Clin Infect Dis. 2009 Jul 15;49(2):315-6; author reply 317. doi: 10.1086/600060. Clin Infect Dis. 2009. PMID: 19538069 No abstract available.
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. Sotgiu G, et al. Among authors: de lorenzo s. Eur Respir J. 2012 Dec;40(6):1430-42. doi: 10.1183/09031936.00022912. Epub 2012 Apr 10. Eur Respir J. 2012. PMID: 22496332 Free article. Review.
Tuberculosis a re-emerging disease.
De Lorenzo S, Tiberi S. De Lorenzo S, et al. Intern Emerg Med. 2012 Oct;7 Suppl 3:S185-7. doi: 10.1007/s11739-012-0822-9. Intern Emerg Med. 2012. PMID: 23073855
Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
Tiberi S, De Lorenzo S, Centis R, Viggiani P, D'Ambrosio L, Migliori GB. Tiberi S, et al. Among authors: de lorenzo s. Eur Respir J. 2014 Jan;43(1):289-92. doi: 10.1183/09031936.00122313. Epub 2013 Aug 29. Eur Respir J. 2014. PMID: 23988772 Free article. No abstract available.
Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.
Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW. Bolhuis MS, et al. Among authors: de lorenzo s. Eur Respir J. 2015 Oct;46(4):1205-7. doi: 10.1183/13993003.00606-2015. Epub 2015 Jul 9. Eur Respir J. 2015. PMID: 26160870 Free article. No abstract available.
121 results